Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,041 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects.
Boyce M, David O, Darwin K, Mitchell T, Johnston A, Warrington S. Boyce M, et al. Among authors: mitchell t. Aliment Pharmacol Ther. 2012 Jul;36(2):181-9. doi: 10.1111/j.1365-2036.2012.05143.x. Epub 2012 May 20. Aliment Pharmacol Ther. 2012. PMID: 22607579 Free article. Clinical Trial.
Phase I study on safety and pharmacokinetics of a novel influenza endonuclease inhibitor, AL-794 (JNJ-64155806), following single- and multiple-ascending doses in healthy adults.
Kakuda TN, Yogaratnam J, Rito J, Boyce M, Mitchell T, Gupta K, Symons JA, Chanda S, Van Remoortere P, Fry J. Kakuda TN, et al. Among authors: mitchell t. Antivir Ther. 2018;23(7):555-566. doi: 10.3851/IMP3244. Epub 2018 Jun 21. Antivir Ther. 2018. PMID: 29927386 Clinical Trial.
Antiviral Activity, Safety, and Pharmacokinetics of AL-794, a Novel Oral Influenza Endonuclease Inhibitor: Results of an Influenza Human Challenge Study.
Yogaratnam J, Rito J, Kakuda TN, Fennema H, Gupta K, Jekle CA, Mitchell T, Boyce M, Sahgal O, Balaratnam G, Chanda S, Van Remoortere P, Symons JA, Fry J. Yogaratnam J, et al. Among authors: mitchell t. J Infect Dis. 2019 Jan 7;219(2):177-185. doi: 10.1093/infdis/jiy410. J Infect Dis. 2019. PMID: 30053042 Clinical Trial.
Protecting scientific integrity in an age of generative AI.
Blau W, Cerf VG, Enriquez J, Francisco JS, Gasser U, Gray ML, Greaves M, Grosz BJ, Jamieson KH, Haug GH, Hennessy JL, Horvitz E, Kaiser DI, London AJ, Lovell-Badge R, McNutt MK, Minow M, Mitchell TM, Ness S, Parthasarathy S, Perlmutter S, Press WH, Wing JM, Witherell M. Blau W, et al. Among authors: mitchell tm. Proc Natl Acad Sci U S A. 2024 May 28;121(22):e2407886121. doi: 10.1073/pnas.2407886121. Epub 2024 May 21. Proc Natl Acad Sci U S A. 2024. PMID: 38771193 Free PMC article. No abstract available.
Equity in clinical trials for hepatitis B.
Mitchell T, Nayagam JS, Mbelle MN, Kabagambe K, Agarwal K. Mitchell T, et al. Lancet Gastroenterol Hepatol. 2024 Jun;9(6):501-502. doi: 10.1016/S2468-1253(24)00083-9. Lancet Gastroenterol Hepatol. 2024. PMID: 38734004 No abstract available.
Corrigendum to 'Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma': [Annals of Oncology 34 (2023) 806-812].
Sharon CE, Tortorello GN, Ma KL, Huang AC, Xu X, Giles LR, McGettigan S, Kreider K, Schuchter LM, Mathew AJ, Amaravadi RK, Gimotty PA, Miura JT, Karakousis GC, Mitchell TC. Sharon CE, et al. Among authors: mitchell tc. Ann Oncol. 2024 Apr 13:S0923-7534(24)00076-0. doi: 10.1016/j.annonc.2024.03.002. Online ahead of print. Ann Oncol. 2024. PMID: 38614876 No abstract available.
2,041 results